Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases

The FDA accepted for filing CorMedix partner Mundipharma’s supplemental NDA for REZZAYO to prevent invasive fungal disease and granted Priority Review, with a target decision date in Q1 2027. The application is supported by positive topline results from the Phase III ReSPECT study in adults undergoing allogeneic HSCT. If approved, CorMedix is targeting promotional efforts starting in H2 2027.

Analysis

The filing acceptance is a procedural de-risking, not new clinical evidence: the pivotal readout is already public, while the full dataset and FDA’s view of its benefit-risk profile remain the key unknowns. Priority Review brings a near-term binary catalyst in Q1 2027, but commercial value is conditional on approval, label breadth, and economics retained by CorMedix under its Mundipharma partnership—none of which is quantified here.

If approved, the most credible adoption wedge is convenience in allogeneic HSCT, not automatic displacement of established prophylaxis. Transplant centers will weigh weekly administration against the efficacy, safety, interaction profile, cost, and workflow of existing regimens, including generic azoles. Thus a positive regulatory outcome may not translate quickly into material revenue; the stated H2 2027 promotional start leaves an execution gap, and uptake data will matter more than launch language.

Near term, CRMD may trade on approval probability and event positioning. Over 1–3 months, monitor complete ReSPECT data, FDA information requests or advisory-committee signals, and disclosure of partner economics. Over 6–18 months, the test is formulary access and repeat use in the narrow transplant population. The contrarian risk is treating a priority review designation as equivalent to a likely approval or a large earnings contribution. The thesis weakens materially if the FDA identifies unresolved efficacy/safety issues, the label is restricted, or early adoption fails to displace existing practice.

Key Decisions for Investors

• Do not chase the filing announcement as if it were a fresh clinical readout. For event-driven exposure, size CRMD around the Q1 2027 FDA binary and assume a sharp downside move is possible; reassess after reviewing full ReSPECT results and the terms of CorMedix’s economics with Mundipharma.
• Set an alert for the complete trial dataset and any FDA review milestones. Focus on endpoint results, safety, comparator details, and whether the proposed label covers the intended allogeneic HSCT population; these determine whether convenience can overcome entrenched prophylaxis.
• Treat post-approval revenue as unproven until CorMedix or Mundipharma provides launch and access metrics. Track formulary adoption, center-level utilization, and any disclosed contribution or royalty structure before underwriting meaningful earnings impact.
• Falsifiers: a restrictive FDA label or review concern; commercial terms that leave CorMedix with limited upside; or weak early transplant-center uptake. Conversely, a clean review, broad usable label, and evidence of repeat adoption would support revisiting the risk/reward after the regulatory event.